Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CDT Equity Inc. filings document a Nasdaq-listed biopharmaceutical issuer with common stock and redeemable warrants, a Delaware corporate structure, and an R&D-focused business built around clinical assets, intellectual property and strategic investments. Current reports and proxy materials cover material agreements, Sarborg-related securities transactions, equity line arrangements, warrant issuances, resale registration obligations and Nasdaq shareholder-approval matters.
The filing record also addresses capital-structure changes such as reverse stock split amendments, voting results, director appointments, committee membership and Exchange Act reporting status, including annual-report timing notices. These disclosures describe CDT's governance framework, security-holder rights and financing tools.
CDT Equity Inc. completed a corporate rebranding, changing its name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. and amending its bylaws to reflect the Name Change. The company confirmed its common stock will continue to trade on The Nasdaq Capital Market under the ticker CDT, and stated the CUSIP for the common stock will not change.
At its annual meeting, stockholders approved an amendment and restatement of the 2023 Stock Incentive Plan to authorize an additional 2,000,000 shares for awards. Stockholders also ratified CBIZ CPAs P.C. as the independent auditor and elected five director nominees. The board appointed James Bligh, a co-founder and interim CFO, as the company’s permanent Chief Financial Officer; he will remain a member of the board and his compensation remains as disclosed in the company’s proxy.